NCT00808795View on ClinicalTrials.gov

Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Radiocontrast-Induced NephropathyChronic Kidney DiseaseDiabetes Mellitus
Interventions
DRUG

N-acetylcysteine

NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).

DRUG

Placebo

Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).

Trial Locations (1)

1411713138

Tehran Heart center, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT00808795 - Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter